{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:12Z","timestamp":1790409252413,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    The physical and emotional burden of relapsed or refractory multiple myeloma (RRMM) has been strongly correlated with declining health\u2010related quality of life (QOL) in the patients it affects. This analysis evaluated patient\u2010reported outcomes (PROs) from B\u2010cell maturation antigen (BCMA)\u2010naive (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009123) and \u2010exposed (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200964) patients with RRMM enrolled in the MagnetisMM\u20103 study (NCT04649359) and treated with the humanized, bispecific BCMA\u2010CD3 antibody elranatamab. Patients received two step\u2010up doses of elranatamab (12\u2009mg on day 1, 32\u2009mg on day 4) before starting the full dose of 76\u2009mg on day 8 (each cycle\u2009=\u200928\u2009days). Global health status, functioning and symptom data were collected electronically using validated and myeloma\u2010specific questionnaires. Improvements in PROs occurred early, with marked reductions in pain and disease symptoms and notable improvements in patients\u2019 outlook for their future health. Additionally, 40.2% of BCMA\u2010naive and 52.6% of BCMA\u2010exposed patients perceived their disease as \u2018a little better\u2019 or \u2018much better\u2019 by Cycle 1, Day 15. The results from this analysis demonstrated that elranatamab maintained or improved symptomology and general health status, regardless of prior BCMA\u2010directed therapy. Thus, in addition to its clinical benefits, elranatamab therapy may sustain or improve QOL in heavily pretreated patients with RRMM.\n                  <\/jats:p>","DOI":"10.1111\/bjh.19346","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T03:55:27Z","timestamp":1709178927000},"page":"1801-1810","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of elranatamab on quality of life: Patient\u2010reported outcomes from\n                    <scp>MagnetisMM<\/scp>\n                    \u20103"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8536-7781","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[{"name":"Sorbonne University, H\u00f4pital Saint\u2010Antoine, and INSERM UMRS 938  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[{"name":"Arnie Charbonneau Cancer Institute, University of Calgary  Calgary Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-4676","authenticated-orcid":false,"given":"Marco","family":"DiBonaventura","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinma","family":"Ren","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Conte","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10101-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17887"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02392-6"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14236007"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.10.002"},{"issue":"5","key":"e_1_2_9_7_1","first-page":"513","article-title":"Patient\u2010reported outcomes and assessment of quality of life: a focus on multiple myeloma","volume":"11","author":"Fragola M","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e18615"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00543-y"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.09.032"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.2842"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0007"},{"issue":"1","key":"e_1_2_9_14_1","first-page":"1","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM\u20101 phase 1 trial","volume":"102","author":"Bahlis NJ","year":"2023","journal-title":"Nat Med"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8006"},{"key":"e_1_2_9_16_1","unstructured":"Elranatamab\u2010bcmm (ELREXFIO) [package insert].2023. Pfizer; New York NY. [cited 2023 Aug 30]. Available from:https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19669"},{"key":"e_1_2_9_17_1","unstructured":"New treatment option for heavily pre\u2010treated multiple myeloma patients: European Medicines Agency.2023. Available from:https:\/\/www.ema.europa.eu\/en\/news\/new\u2010treatment\u2010option\u2010heavily\u2010pre\u2010treated\u2010multiple\u2010myeloma\u2010patients"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00284-8"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00815-9"},{"key":"e_1_2_9_22_1","unstructured":"Guidance for Industry: Expedited Programs for Serious Conditions \u2010 Drugs and Biologics: Food and Drug Administration (FDA).2014. Available from:https:\/\/www.hhs.gov\/guidance\/sites\/default\/files\/hhs\u2010guidance\u2010documents\/Expedited\u2010Programs\u2010for\u2010Serious\u2010Conditions__Drugs\u2010and\u2010Biologics.pdf"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-35"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.07.013"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2017.09.007"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005913"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8033"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01788.x"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01404.x"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<667::AID-SIM813>3.0.CO;2-6"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010938"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T03:42:36Z","timestamp":1730691756000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/bjh.19346"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19346","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"2023-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}